NORDIC | BIOTECH & HEALTHCARE Your insights into listed Danish & Nordic biotech & healthcare stocks.
In the past week, the Danish biotech and healthcare sector delivered a negative return of 4.5%. Acarix received reimbursement in the U.S., while FluoGuide and Genmab presented positive results. 2cureX continues to be the odd one return-wise, with a stock price return of almost 10x year-to-date. The year-to-date return for the Danish biotech and healthcare stocks is 40.6%, including 2cureX, while it is -8.2% excluding 2cureX.
Latest news for the Danish biotech companies
Acarix AB has developed a technology to identify heart diseases. Moving forward, product sales are the main driver for the stock.
Acarix has just announced its first fixed U.S. reimbursement milestone for CADScor at USD 300.
Ascendis Pharma develops so-called prodrugs, which are medications that start in an inactive form and become active once inside the body. The main stock price driver going forward is the development and commercialization of its TransCon technology.
Ascendis announced interim analysis results of its phase II COACH trail with TransCon.
Biosergen is developing BSG005 to treat serious and life-threatening fungal infections safely and with limited side effects, contrary to current drugs. The main price triggers are centered around product development and the ongoing clinical trials
No news in the past week
Cessatech develops pain treatments for children. The company is finalizing its phase 3 study for its lead candidate, and the main price driver will be the commercialization for this product.
Cessatech announce completion of the directed issue of shares following their directed share issue of MDKK 14.8
Curasight is focused on diagnosing (uTRACE) and treating cancer (uTREAT) through targeted radionuclide therapy. The benefit is treating cancer at the cellular level without harming healthy cells. The main driver of the stock moving forward is the financing of the portfolio as well as pipeline and partnership development. You can read our full investment case here (in Danish).
No news in the past week
DanCann Pharma focuses on discovering, developing, and producing medical cannabis for pain and neurological conditions. The stock price drivers are regulatory progress and sales development.
No news in the past week
Evaxion Biotech develops personalized immunotherapies and vaccines, with recent advancements in their cancer vaccine candidate EVX-01. Clinical trial outcomes and technological innovations currently drive the stock price.
No news in the past week
ExpreS2ion provides protein production technologies for vaccine development and has its own pipeline. Key stock drivers include pipeline progression and licensing agreements.
No news in the past week
Fluoguide develops tumor-targeted products that make cancer visible on imaging solutions to improve cancer surgery outcomes, especially within brain and head & neck cancer surgery. The main stock driver is the clinical validation of their imaging technology and additional partnerships.
FluoGuide published phase I clinical data with FG001 in Neurosurgery. The data is the first-in-human result of its proprietary near-infrared (NIR) optical imaging agent, FG001, in patients with malignant glioma undergoing surgery.
Genmab focuses on creating differentiated antibody therapeutics for the treatment of lymphatic leukemia and solid tumors. Genmab has developed Darzalex, with sales of nearly USD 12 billion in 2024. The stock performance is primarily driven by product sales and pipeline developments.
Genmab announced that their Epcoritamab investigational combination therapy demonstrates high response rates in patients with relapsed or refractory (R/R) diffuse large B-Cell lymphoma (DLBCL) eligible for autologous stem cell transplantation (ASCT)
Gubra offers preclinical contract research services and develops treatments for metabolic diseases. Key stock drivers are partnerships and progress in their internal drug pipeline.
No news in the past week
Initiator Pharma develops treatments for erectile dysfunction and neuropathic pain. The main stock catalyst is the outcome of clinical trials.
Initiator Pharma is ongoing with its rights issue of MSEK 56, which is 86% secured. The subscription period runs from the 12-26 June 2025.
IO Biotech is developing immune-modulating therapies for cancer, with a focus on conditions like melanoma. Stock performance is driven by clinical trial advancements.
No news in the past week
Pila Pharma is working on TRPV1 antagonists aimed at treating type 2 diabetes. Early clinical data and funding developments are key stock drivers.
No news in the past week
Saniona focuses on ion channel-targeted therapies, including rare eating disorders. The main stock driver is the progression of their clinical pipeline and the approval of the weight loss drug Tesofensine in Mexico.
No news in the past week
Scandion Oncology is developing treatments to overcome chemotherapy resistance in cancer patients. The company has recently faced significant financial challenges; thus, financial stability is the main driver for the stock price.
No news in the past week
SynAct Pharma develops drugs targeting inflammatory diseases through melanocortin pathways. Clinical milestones significantly influence stock performance
No news in the past week
ViroGates provides prognostic products for acute care settings to improve patient triage. Stock drivers include hospital adoption rates and revenue growth.
No news in the past week
Y-mAbs Therapeutics develops antibody-based therapies for pediatric cancers. Stock performance is driven by regulatory approvals and commercialization efforts.
No news in the past week
Zealand Pharma specializes in peptide-based treatments for metabolic and gastrointestinal diseases. The stock has seen increased awareness following the obesity hype, and advancements in its late-stage pipeline and partnerships are key stock price influencers.
No news in the past week
2cureX offers the IndiTreat platform for individualized cancer treatment testing. The main stock driver is the adoption of their technology by hospitals and subsequent sales growth.
No news in the past week
The latest share price developments for the Danish biotech stocks
On average, the Danish biotech and healthcare stocks delivered a negative return of 4.5%. Most notably, Acarix announced its first fixed reimbursement in the U.S. Additionally, Fluoguide presented phase I clinical data for FG001 in neurosurgery, of which the CEO was very pleased. Genmab also announced positive results for Epcoritamab in combination therapy, demonstrating high response rates in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma, while Initiator Pharma is ongoing with its MSEK 56 rights issue. The odd one out continues to be 2cureX. Year-to-date, the average return is 40.6%, including 2cureX, while it is -8.2% excluding 2cureX, which essentially means being invested in 2cureX has been the deciding factor if you have a positive return or not in the Danish biotech stocks year-to-date.
Overview of share price development in the past week, year-to-date, and the last twelve months
DanCann Pharma does not appear on the list due to data issues.
Inhalation Sciences AB is raising capital; you can participate!
SpectraCure AB focuses on cancer treatments using medical devices with laser light sources and photoreactive drugs called “interstitial photodynamic therapy”, PDT, to target solid tumors. The company wants to raise MSEK 84, and the subscription period runs until June 19, 2025.
